newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

SER
  • FDA granted IND clearance for SER-252 in January 2026 for advanced Parkinson's disease treatment.
  • Serina Therapeutics dosed the first patient in the SER-252 Phase 1b registrational trial in February 2026.
  • Company completed a private placement financing on March 17, 2026, raising initial gross proceeds of $16.0 million of a potential up to $30 million total.
  • Greg Bailey, M.D., led the financing \& assumed the role of Co-Chairman alongside Simba Gill, Ph.D.
  • The private placement included 50% warrant coverage, offering potential additional proceeds of up to $33.3 million from future warrant exercises.
  • An existing Senior Unsecured Convertible Promissory Note was amended to remove further borrowing obligations as part of the financing closing.
  • Through the At-the-Market (ATM) Equity Program in 2026, Serina sold 3.0 million shares for $10.0 million in gross proceeds.
  • Total ATM proceeds to date amount to $12.9 million from the sale of 3.5 million shares at a gross average price of $3.72 per share.
  • Research and development expenses increased to $13.2 million in 2025 from $7.5 million in 2024 due to clinical activities, headcount, \& outsourced services.
  • General and administrative expenses rose to $11.0 million in 2025 from $9.6 million in 2024, driven by stock-based compensation \& public company infrastructure costs.
  • Net loss attributable to common stockholders was $19.4 million ($1.91 per share) for 2025, compared to $11.1 million ($1.51 per share) in 2024.
  • Cash \& cash equivalents totaled $3.1 million as of December 31, 2025.
  • SER-252 is designed to provide continuous dopaminergic stimulation via subcutaneous injection to reduce levodopa-related motor complications.
  • The SER-252 Phase 1b trial is a randomized, double-blind, placebo-controlled study across the U.S. \& Australia evaluating safety, tolerability, \& pharmacokinetics.
  • SER-270, an investigational once-weekly VMAT2 inhibitor, is being developed for tardive dyskinesia using the POZ platform.
  • Serina holds a non-exclusive license agreement with Pfizer, Inc. to utilize its POZ polymer technology for lipid nanoparticle drug delivery formulations.